Bausch Health (BHC) reported $2.85 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.7%. EPS of $1.26 for the same period compares to $0.90 a year ago.
The reported revenue represents a surprise of +7.62% over the Zacks Consensus Estimate of $2.65 billion. With the consensus EPS estimate being $0.96, the EPS surprise was +31.25%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Total Bausch + Lomb revenues: $1.39 billion versus $1.34 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change. Revenues- Diversified Products: $219 million versus the two-analyst average estimate of $199.83 million. The reported number represents a year-over-year change of 0%. Revenues- Bausch + Lomb- Vision Care: $784 million versus the two-analyst average estimate of $782.41 million. The reported number represents a year-over-year change of +4.1%. Revenues- Bausch + Lomb- Surgical: $256 million compared to the $232.49 million average estimate based on two analysts. The reported number represents a change of +18.5% year over year. Revenues- Bausch + Lomb- Pharmaceuticals: $354 million versus $326.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change. Revenues- International: $305 million compared to the $292.25 million average estimate based on two analysts. The reported number represents a change of +9.7% year over year. Revenues- Total Bausch Health (excl. B+L): $1.46 billion compared to the $1.31 billion average estimate based on two analysts. The reported number represents a change of +16.5% year over year. Revenues- Solta Medical: $176 million versus the two-analyst average estimate of $170.13 million. The reported number represents a year-over-year change of +37.5%. Revenues- Diversified Products- Neuroscience: $138 million versus the two-analyst average estimate of $120.21 million. The reported number represents a year-over-year change of +17%. Revenues- Diversified Products- Generics: $14 million versus the two-analyst average estimate of $18.7 million. The reported number represents a year-over-year change of -33.3%. Revenues- Diversified Products- Dentistry: $20 million versus the two-analyst average estimate of $21.43 million. The reported number represents a year-over-year change of -20%. Revenues- Salix: $758 million versus the two-analyst average estimate of $646.3 million. The reported number represents a year-over-year change of +20.9%.View all Key Company Metrics for Bausch here>>>
Shares of Bausch have returned -8.3% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch Health Cos Inc. (BHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).